{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:00:15Z","timestamp":1794916815838,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-63377-3","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T01:17:42Z","timestamp":1756257462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Reprogramming the tumor microenvironment with c-MYC-based gene circuit platform to enhance specific cancer immunotherapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Hengji","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3438-0297","authenticated-orcid":false,"given":"Junlin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanghua","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajian","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwen","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-8697","authenticated-orcid":false,"given":"Tianxin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8425-036X","authenticated-orcid":false,"given":"Xu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"63377_CR1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"63377_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.it.2016.04.008","volume":"37","author":"S Spranger","year":"2016","unstructured":"Spranger, S. Tumor heterogeneity and tumor immunity: a chicken-and-egg problem. Trends Immunol. 37, 349\u2013351 (2016).","journal-title":"Trends Immunol."},{"key":"63377_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613\u2013628 (2017).","journal-title":"Cell"},{"key":"63377_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479\u2013485 (2019).","journal-title":"Nature"},{"key":"63377_CR5","doi-asserted-by":"publisher","unstructured":"Reuben, A. et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom. Med. https:\/\/doi.org\/10.1038\/s41525-017-0013-8 (2017).","DOI":"10.1038\/s41525-017-0013-8"},{"key":"63377_CR6","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"63377_CR7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","volume":"27","author":"I Vitale","year":"2021","unstructured":"Vitale, I., Shema, E., Loi, S. & Galluzzi, L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat. Med. 27, 212\u2013224 (2021).","journal-title":"Nat. Med."},{"key":"63377_CR8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","volume":"618","author":"A Gavish","year":"2023","unstructured":"Gavish, A. et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature 618, 598\u2013606 (2023).","journal-title":"Nature"},{"key":"63377_CR9","doi-asserted-by":"publisher","unstructured":"Quinn, J. J. et al. Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science https:\/\/doi.org\/10.1126\/science.abc1944 (2021).","DOI":"10.1126\/science.abc1944"},{"key":"63377_CR10","doi-asserted-by":"publisher","first-page":"112401","DOI":"10.1016\/j.celrep.2023.112401","volume":"42","author":"C Liu","year":"2023","unstructured":"Liu, C., Kudo, T., Ye, X. & Gascoigne, K. Cell-to-cell variability in Myc dynamics drives transcriptional heterogeneity in cancer cells. Cell Rep. 42, 112401 (2023).","journal-title":"Cell Rep."},{"key":"63377_CR11","doi-asserted-by":"publisher","first-page":"22399","DOI":"10.1073\/pnas.1903485116","volume":"116","author":"P Kreuzaler","year":"2019","unstructured":"Kreuzaler, P. et al. Heterogeneity of Myc expression in breast cancer exposes pharmacological vulnerabilities revealed through executable mechanistic modeling. Proc. Natl Acad. Sci. USA 116, 22399\u201322408 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"63377_CR12","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1158\/2159-8290.CD-20-1826","volume":"12","author":"R Maddipati","year":"2022","unstructured":"Maddipati, R. et al. MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma. Cancer Discov. 12, 542\u2013561 (2022).","journal-title":"Cancer Discov."},{"key":"63377_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","volume":"3","author":"H Chen","year":"2018","unstructured":"Chen, H., Liu, H. & Qing, G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct. Target Ther. 3, 5 (2018).","journal-title":"Signal Transduct. Target Ther."},{"key":"63377_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","volume":"151","author":"CY Lin","year":"2012","unstructured":"Lin, C. Y. et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151, 56\u201367 (2012).","journal-title":"Cell"},{"key":"63377_CR15","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/neuonc\/noac068","volume":"24","author":"N Qin","year":"2022","unstructured":"Qin, N. et al. Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis. Neuro Oncol. 24, 1509\u20131523 (2022).","journal-title":"Neuro Oncol."},{"key":"63377_CR16","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1158\/2159-8290.CD-22-0796","volume":"13","author":"LS Pongor","year":"2023","unstructured":"Pongor, L. S. et al. Extrachromosomal DNA amplification contributes to small cell lung cancer heterogeneity and is associated with worse outcomes. Cancer Discov. 13, 928\u2013949 (2023).","journal-title":"Cancer Discov."},{"key":"63377_CR17","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41587-020-00805-3","volume":"39","author":"DSC Butler","year":"2021","unstructured":"Butler, D. S. C. et al. A bacterial protease depletes c-MYC and increases survival in mouse models of bladder and colon cancer. Nat. Biotechnol. 39, 754\u2013764 (2021).","journal-title":"Nat. Biotechnol."},{"key":"63377_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41587-022-01504-x","volume":"41","author":"TE Speltz","year":"2023","unstructured":"Speltz, T. E. et al. Targeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains. Nat. Biotechnol. 41, 541\u2013551 (2023).","journal-title":"Nat. Biotechnol."},{"key":"63377_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41580-020-0215-2","volume":"21","author":"A Baluapuri","year":"2020","unstructured":"Baluapuri, A., Wolf, E. & Eilers, M. Target gene-independent functions of MYC oncoproteins. Nat. Rev. Mol. Cell Biol. 21, 255\u2013267 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"63377_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"Dang, C. V. MYC on the path to cancer. Cell 149, 22\u201335 (2012).","journal-title":"Cell"},{"key":"63377_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nature13473","volume":"511","author":"S Walz","year":"2014","unstructured":"Walz, S. et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature 511, 483\u2013487 (2014).","journal-title":"Nature"},{"key":"63377_CR22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","volume":"28","author":"AV Finck","year":"2022","unstructured":"Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G. & June, C. H. Engineered cellular immunotherapies in cancer and beyond. Nat. Med. 28, 678\u2013689 (2022).","journal-title":"Nat. Med."},{"key":"63377_CR23","doi-asserted-by":"publisher","unstructured":"Wang, Y. et al. Challenges coexist with opportunities: spatial heterogeneity expression of PD-L1 in cancer therapy. Adv. Sci. https:\/\/doi.org\/10.1002\/advs.202303175 (2023).","DOI":"10.1002\/advs.202303175"},{"key":"63377_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","volume":"21","author":"KJ Hiam-Galvez","year":"2021","unstructured":"Hiam-Galvez, K. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in cancer. Nat. Rev. Cancer 21, 345\u2013359 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"63377_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ccell.2019.10.001","volume":"36","author":"H Han","year":"2019","unstructured":"Han, H. et al. Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy. Cancer Cell 36, 483\u2013497.e415 (2019).","journal-title":"Cancer Cell"},{"key":"63377_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227\u2013231 (2016).","journal-title":"Science"},{"key":"63377_CR27","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S1470-2045(21)00353-3","volume":"22","author":"The Lancet","year":"2021","unstructured":"Lancet, T. he O. CAR T-cell therapy for solid tumours. Lancet Oncol. 22, 893 (2021).","journal-title":"Lancet Oncol."},{"key":"63377_CR28","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cell.2019.04.041","volume":"177","author":"L Gauthier","year":"2019","unstructured":"Gauthier, L. et al. Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. Cell 177, 1701\u20131713.e1716 (2019).","journal-title":"Cell"},{"key":"63377_CR29","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1200\/JCO.23.00580","volume":"42","author":"B Ricciuti","year":"2024","unstructured":"Ricciuti, B. et al. Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer. J. Clin. Oncol.42, 1311\u20131321 (2024).","journal-title":"J. Clin. Oncol."},{"key":"63377_CR30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1101\/gad.10.4.447","volume":"10","author":"L Desbarats","year":"1996","unstructured":"Desbarats, L., Gaubatz, S. & Eilers, M. Discrimination between different E-box-binding proteins at an endogenous target gene of c-myc. Genes Dev. 10, 447\u2013460 (1996).","journal-title":"Genes Dev."},{"key":"63377_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1712-5","volume":"20","author":"H Zhan","year":"2019","unstructured":"Zhan, H. et al. Multiplexed promoterless gene expression with CRISPReader. Genome Biol. 20, 113 (2019).","journal-title":"Genome Biol."},{"key":"63377_CR32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S0962-8924(03)00003-5","volume":"13","author":"M Wanzel","year":"2003","unstructured":"Wanzel, M., Herold, S. & Eilers, M. Transcriptional repression by Myc. Trends Cell Biol. 13, 146\u2013150 (2003).","journal-title":"Trends Cell Biol."},{"key":"63377_CR33","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature02844","volume":"431","author":"L Yen","year":"2004","unstructured":"Yen, L. et al. Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature 431, 471\u2013476 (2004).","journal-title":"Nature"},{"key":"63377_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41587-019-0357-y","volume":"38","author":"G Zhong","year":"2020","unstructured":"Zhong, G. et al. A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in vivo. Nat. Biotechnol. 38, 169\u2013175 (2020).","journal-title":"Nat. Biotechnol."},{"key":"63377_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.cell.2006.06.036","volume":"126","author":"M Martick","year":"2006","unstructured":"Martick, M. & Scott, W. G. Tertiary contacts distant from the active site prime a ribozyme for catalysis. Cell 126, 309\u2013320 (2006).","journal-title":"Cell"},{"key":"63377_CR36","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/s41587-022-01624-4","volume":"41","author":"DM Ichikawa","year":"2023","unstructured":"Ichikawa, D. M. et al. A universal deep-learning model for zinc finger design enables transcription factor reprogramming. Nat. Biotechnol. 41, 1117\u20131129 (2023).","journal-title":"Nat. Biotechnol."},{"key":"63377_CR37","doi-asserted-by":"publisher","first-page":"e3377","DOI":"10.1371\/journal.pone.0003377","volume":"3","author":"VR Simhadri","year":"2008","unstructured":"Simhadri, V. R. et al. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS ONE 3, e3377 (2008).","journal-title":"PLoS ONE"},{"key":"63377_CR38","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1807","volume":"29","author":"L Alvarez-Erviti","year":"2011","unstructured":"Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341\u2013345 (2011).","journal-title":"Nat. Biotechnol."},{"key":"63377_CR39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/sj.gt.3301080","volume":"7","author":"KW Liao","year":"2000","unstructured":"Liao, K. W., Lo, Y. C. & Roffler, S. R. Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells. Gene Ther. 7, 339\u2013347 (2000).","journal-title":"Gene Ther."},{"key":"63377_CR40","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/sj.cgt.7700637","volume":"10","author":"KW Liao","year":"2003","unstructured":"Liao, K. W. et al. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity. Cancer Gene Ther. 10, 779\u2013790 (2003).","journal-title":"Cancer Gene Ther."},{"key":"63377_CR41","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.cell.2017.09.049","volume":"171","author":"L Nissim","year":"2017","unstructured":"Nissim, L. et al. Synthetic RNA-based immunomodulatory gene circuits for cancer immunotherapy. Cell 171, 1138\u20131150.e1115 (2017).","journal-title":"Cell"},{"key":"63377_CR42","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrd2482","volume":"7","author":"K Skak","year":"2008","unstructured":"Skak, K., Kragh, M., Hausman, D., Smyth, M. J. & Sivakumar, P. V. Interleukin 21: combination strategies for cancer therapy. Nat. Rev. Drug Discov. 7, 231\u2013240 (2008).","journal-title":"Nat. Rev. Drug Discov."},{"key":"63377_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31238-y","volume":"13","author":"JV Lee","year":"2022","unstructured":"Lee, J. V. et al. Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. Nat. Commun. 13, 3671 (2022).","journal-title":"Nat. Commun."},{"key":"63377_CR44","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","volume":"35","author":"D Dangaj","year":"2019","unstructured":"Dangaj, D. et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell 35, 885\u2013900.e810 (2019).","journal-title":"Cancer Cell"},{"key":"63377_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10330-w","volume":"10","author":"KS Farquhar","year":"2019","unstructured":"Farquhar, K. S. et al. Role of network-mediated stochasticity in mammalian drug resistance. Nat. Commun. 10, 2766 (2019).","journal-title":"Nat. Commun."},{"key":"63377_CR46","doi-asserted-by":"publisher","first-page":"586726","DOI":"10.3389\/fgene.2020.586726","volume":"11","author":"MT Guinn","year":"2020","unstructured":"Guinn, M. T. et al. Observation and control of gene expression noise: barrier crossing analogies between drug resistance and metastasis. Front. Genet. 11, 586726 (2020).","journal-title":"Front. Genet."},{"key":"63377_CR47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden, M. & Spranger, S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat. Rev. Immunol. 25, 353\u2013369 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"63377_CR48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li, C. & Samulski, R. J. Engineering adeno-associated virus vectors for gene therapy. Nat. Rev. Genet. 21, 255\u2013272 (2020).","journal-title":"Nat. Rev. Genet."},{"key":"63377_CR49","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell, S. et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390, 849\u2013860 (2017).","journal-title":"Lancet"},{"key":"63377_CR50","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss, K. A. et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat. Med. 28, 1390\u20131397 (2022).","journal-title":"Nat. Med."},{"key":"63377_CR51","doi-asserted-by":"publisher","first-page":"e2205613","DOI":"10.1002\/advs.202205613","volume":"10","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q. et al. ETV4 mediated tumor-associated neutrophil infiltration facilitates lymphangiogenesis and lymphatic metastasis of bladder cancer. Adv. Sci. 10, e2205613 (2023).","journal-title":"Adv. Sci."},{"key":"63377_CR52","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41596-018-0112-8","volume":"14","author":"G Lorenzatti Hiles","year":"2019","unstructured":"Lorenzatti Hiles, G. et al. A surgical orthotopic approach for studying the invasive progression of human bladder cancer. Nat. Protoc. 14, 738\u2013755 (2019).","journal-title":"Nat. Protoc."},{"key":"63377_CR53","doi-asserted-by":"publisher","unstructured":"Hong, X. et al. A HER2-targeted antibody-drug conjugate, RC48-ADC, exerted promising antitumor efficacy and safety with intravesical instillation in preclinical models of bladder cancer. Adv. Sci. https:\/\/doi.org\/10.1002\/advs.202302377 (2023).","DOI":"10.1002\/advs.202302377"},{"key":"63377_CR54","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1158\/0008-5472.CAN-22-2233","volume":"83","author":"R Xie","year":"2023","unstructured":"Xie, R. et al. NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer. Cancer Res. 83, 1666\u20131683 (2023).","journal-title":"Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63377-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63377-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63377-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:27:38Z","timestamp":1757442458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63377-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["63377"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-63377-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7983"}}